Navigation Links
Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
Date:2/27/2008

ence call will be available for replay through March 12, 2008.

To access the conference call, follow these instructions:

Dial: (866) 314-5232 (U.S.); (617) 213-8052 (international)

Passcode: 94561493 (Howard Robin is the host)

Audio replay dial-in and passcode:

Dial: (888) 286-8010 (U.S.) ;(617) 801-6888 (international)

Passcode: 92959414

About Nektar

Nektar Therapeutics is a biopharmaceutical company with a mission to develop and enable differentiated therapeutics with its industry-leading pulmonary and PEGylation technology platforms. Nektar pulmonary and PEGylation technology, expertise, manufacturing capabilities and know-how have enabled ten approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its pulmonary and PEGylation technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements that reflect the company's current views as to the value of its technology platforms and clinical pipeline of product candidates and overall prospects for the company's business. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) the company's proprietary product candidates and those of certain of its partners are in the early phases of clinical development and the risk of failure is high and can occur at any stage prior to regulatory approval, (ii) the timing or success of the commencement or end of clinical trials is subject to a number of uncertainties including but not limited to patient enrollment, clinical drug manufacturing, regulatory requirements and clinical outcomes, and (iii) the company's or its partner's success in obtaining regulatory approvals for product candidates. Other important risks and uncertainties are det
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
2. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
3. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
4. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
6. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
7. Prime Therapeutics Receives TIPPS Certification
8. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
9. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
10. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
11. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... need surgery for facial pain caused by trigeminal neuralgia, ... reports a study in the September issue of ... Congress of Neurological Surgeons . The journal is published ... of Wolters Kluwer Health . , Percutaneous stereotaxic ... cost than other types of surgical treatments for trigeminal ...
(Date:8/22/2014)... Key West Health & Beauty’s ( ... much anticipated study results of the 12 best and ... an accompanying infographic on their website. It appears that ... major impact on the skin and contribute to many ... When asked how they determined the results, founder and ...
(Date:8/22/2014)... According to the new research ... Global Trends & Forecast to 2019" defines and ... forecast of the market value. The isocyanate material ... 2019, at a significant CAGR from 2014 to ... 44 figures spread through 286 pages and in-depth ...
(Date:8/22/2014)... 22, 2014 Braverman Eye Center is ... Lauderdale at the most affordable fee. They are on ... their advanced Lasik treatments. LASIK is a highly successful ... Eye Center has been delivering successful LASIK solutions to ... glasses-free and contact lenses-free life with the help of ...
(Date:8/22/2014)... A new study finds a wide range of ... related to key environmental exposuresin children with Crohn,s disease (CD), ... of the Crohn,s & Colitis Foundation of America ... & Wilkins , a part of Wolters Kluwer Health ... alterations of DNA in several regions of the genome in ...
Breaking Medicine News(10 mins):Health News:More common procedures for painful facial tics carry high costs, reports study in Neurosurgery 2Health News:Key West Health & Beauty Announces The 12 Best & Worst U.S. Cities For Skin Study 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 3Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 4Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2Health News:Study shows epigenetic changes in children with Crohn's disease 2
... associated protein-1 (TRAP-1) may prevent cancer cell death. The ... as a Novel Molecular Target in Localized and Metastatic Prostate ... American Journal of Pathology . Prostate cancer is the ... cause of cancer deaths among men in the United States, ...
... are not as stringent as with new medications , TUESDAY, ... Administration may not be as stringent in evaluating devices as ... report in the Dec. 23/30 issue of the Journal ... often sails through based on studies that are not randomized ...
... stick to your workout routine, even in foul weather , ... chill on even the most enthusiastic exerciser,s plans. It,s hard ... sidestep icy patches. And who wants to go to the ... windshield first? , But sticking to your exercise program throughout ...
... have replaced the street as easy source of medications, experts ... death of pop star Michael Jackson in 2009 drew new ... States. , And with that attention has come acknowledgment ... five teenagers and adults -- about 50 million Americans -- ...
... the lab, expert says , TUESDAY, Dec. 29 (HealthDay ... cause some germs to develop resistance to antibiotics, new ... outside of the laboratory and they don,t suggest that ... "It is OK to use disinfectants. Just don,t misuse ...
... Texas, Dec. 29 Top marketing representatives ... Global Hotel Alliance brand members recently hosted a unique "Lasso ... The luxury hotel brands from across the world readily joined forces ... GHA associate who succumbed to lymphoma cancer in May. ...
Cached Medicine News:Health News:The cancer 'TRAP' 2Health News:Study Questions FDA Approvals of Cardiac Devices 2Health News:Study Questions FDA Approvals of Cardiac Devices 3Health News:Study Questions FDA Approvals of Cardiac Devices 4Health News: Winter Exercise Can Lift Your Spirits 2Health News:In U.S., Prescription Drug Abuse Is Growing 2Health News:In U.S., Prescription Drug Abuse Is Growing 3Health News:In U.S., Prescription Drug Abuse Is Growing 4Health News:Disinfectant Misuse Might Help Germs Resist Antibiotics 2Health News:Disinfectant Misuse Might Help Germs Resist Antibiotics 3Health News:Omni Hotels & Resorts and Global Hotel Alliance Partner for Charity 2Health News:Omni Hotels & Resorts and Global Hotel Alliance Partner for Charity 3
(Date:8/21/2014)... , Aug. 21, 2014   Memorial Hermann Health System ... Center today announced a new partnership to provide a ... community breast care centers in the greater Houston ... Anderson will become the exclusive provider of professional breast radiology ... located in Memorial City, The Woodlands , ...
(Date:8/21/2014)... 21, 2014 Nektar Therapeutics (NASDAQ: ... announced positive results from its Phase 3 pivotal ... half-life recombinant factor VIII (rFVIII) treatment for hemophilia ... met its primary endpoint in reducing annualized bleed ... the on-demand arm. Top-line results from ...
(Date:8/21/2014)... The spinal column is one of the most delicate and ... from the brain through the column control many key functions ... here can be life altering, and leave the victim in ... body. Though back injury and disease can have an intensely ... available to make things better than ever before. Laser ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2
... 6, 2011 NeuroSigma, Inc., a Los Angeles-based ... a notice of award for an NIH Small ... the National Institute of Neurological Disorders and Stroke ... trigeminal nerve stimulation (eTNS™) therapy for the treatment ...
... NEW YORK, Sept. 6, 2011 ... research report is available in its ... Vaccines - Cell Culture Technology Gradually ... http://www.reportlinker.com/p0610894/Manufacturing-of-Vaccines---Cell-Culture-Technology-Gradually-Replacing-Egg-Based-Manufacturing.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication Manufacturing ...
Cached Medicine Technology:NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy 2Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 2Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 3Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 4Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 5Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 6Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 7